Oncology Evolved

with off-the-shelf cellular therapies for cancer

PIPELINE

PRE-CLINICAL

CLINICAL

AML

WU-NK-101

Head & Neck Cancer

WU-NK-101 + Cetuximab

Melanoma

WU-NK-101 (post-checkpoint inhibitor)

Solid Tumors

WU-NK-201

T-ALL

WU-CART-007

LATEST NEWS

Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting

WU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA   WU-CART-007 demonstrates…

Read more
Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK)…

Read more
Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference

ST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis